Clinical

Dataset Information

Personalized neoantigen peptide vaccine for advanced solid cancer


ABSTRACT: Interventions: Personalized neoantigen peptide vaccine consists of 15-30 long peptides combined into four distinct immunizing peptide pools with 0.3 mg of each peptide admixed with 0.5 mg poly-ICLC per pool in a volume of 1 ml.;Experimental Biological/Vaccine;Personalized Neoantigen Peptide vaccine Primary outcome(s): Overall response rate at week 9, 18 on treatment period and every 12 weeks until disease progression or up to 12 months modified RECIST 1.1

DISEASE(S): Small Cell Lung Cancer (nsclc),Neoantigen Peptide Vaccine,Advanced,Colorectal Cancer (crc),Pancreatic Cancer And Melanoma,Immunotherapy,Metastatic Cancer,Stage Non

PROVIDER: 2568253 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR